文献速递骨质疏松与代谢性骨病

非透析慢性肾病患者肌少症、骨质疏松及骨肌减少症患病率显著高于健康对照

High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls.
PubMed 文献 · Osteoporos Int · 2026-04-20

这项横断面研究将138例CKD G4-5期患者按性别和年龄1:1匹配健康对照,评估肌少症、骨质疏松及骨肌减少症患病率。结果显示CKD患者握力更弱、椅子站立表现更差、步速更慢,BMD更低,三种疾病患病率均显著高于对照。作者建议在CKD管理中系统评估肌肉与骨骼健康。

要点

  • CKD G4-5期患者肌少症患病率21.7%,显著高于健康对照的5.8%(OR 4.51)。
  • CKD患者骨质疏松患病率21.7% vs 对照10.1%(OR 2.44),骨肌减少症8.7% vs 1.4%(OR 6.44)。
  • CKD患者握力更弱、30秒椅子站立表现更差、10米步速更慢,且BMD降低。

核心结论

  • 非透析CKD G4-5期患者肌少症、骨质疏松和骨肌减少症患病率均显著高于性别和年龄匹配的健康对照。
  • 研究结果支持在CKD管理中系统评估肌肉和骨骼健康。

研究设计与样本

  • 横断面研究,纳入138例CKD G4-5期患者,按性别和年龄1:1匹配健康对照。
  • 采用双能X线吸收法评估四肢瘦体重和髋部、腰椎骨密度,通过握力、30秒椅子站立和10米步速评估肌力。
  • 肌少症采用EWGSOP标准,骨质疏松采用WHO标准,骨肌减少症需两者同时存在。

主要发现

  • CKD患者握力更弱、椅子站立表现更差、步速更慢,BMD降低。
  • 肌少症患病率CKD组21.7% vs 对照组5.8%(OR 4.51 [1.91-11.8])。
  • 骨质疏松患病率CKD组21.7% vs 对照组10.1%(OR 2.44 [1.25-4.99])。
  • 骨肌减少症患病率CKD组8.7% vs 对照组1.4%(OR 6.44 [1.39-60.4])。

关键数值与推荐

  • 肌少症定义采用EWGSOP标准,骨质疏松采用WHO标准,骨肌减少症需两者同时满足。

临床怎么用

  • 对非透析CKD G4-5期患者应系统评估肌肉和骨骼健康,包括肌力、步速和骨密度检测。
  • 关注CKD患者中肌少症、骨质疏松及骨肌减少症的高共病风险,以便早期识别和干预。

局限性

  • 横断面设计无法确定因果关系。
  • 样本量有限(138例CKD患者),骨肌减少症的OR置信区间较宽(1.39-60.4)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Brief rationale: The impact of non-dialysis chronic kidney disease (CKD) on combined muscle and bone decline remains insufficiently described. MAIN RESULT: Patients with CKD showed markedly higher rates of sarcopenia, osteoporosis, and osteosarcopenia than matched healthy controls. Significance of the paper: These findings support systematic evaluation of muscle and bone health in CKD management. PURPOSE: Chronic kidney disease (CKD) negatively affects bone and muscle quality. The combination of sarcopenia and osteoporosis, osteosarcopenia, is associated with an increased risk of fractures and mortality. Yet, little is known about osteosarcopenia in patients with non-dialysis-dependent CKD compared to healthy controls. We hypothesized that patients with CKD have a higher prevalence of osteosarcopenia than healthy adults. METHODS: In this cross-sectional study, 138 patients with CKD stages G4-5 were matched 1:1 on sex and age to healthy controls. We assessed appendicular lean mass and bone mineral density (BMD) at the hips and lumbar spine using dual-energy X-ray absorptiometry and evaluated muscle strength through handgrip strength, 30-s chair stands, and 10-m gait speed. Sarcopenia was defined using the criteria by the EWGSOP criteria, osteoporosis by the WHO criteria, and osteosarcopenia required the presence of both. RESULTS: CKD participants had weaker handgrip strength, poorer chair-stand performance, and slower gait speed compared to healthy controls. BMD was reduced in patients with CKD. The prevalence of sarcopenia (21.7% vs. 5.8%; OR 4.51 [1.91-11.8]), osteoporosis (21.7% vs. 10.1%; OR 2.44 [1.25-4.99]), and osteosarcopenia (8.7% vs 1.4%; OR 6.44 [1.39-60.4]) were higher in patients with CKD compared to controls. CONCLUSION: In this cross-sectional study, there was a higher prevalence of sarcopenia, osteoporosis, and osteosarcopenia in patients with CKD as compared to sex- and age-matched healthy controls. These findings indicate that it is relevant with a systematic assessment of muscle and bone health in CKD management.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Rashid A, Hauge SC, Nielsen BR, et al. High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls. Osteoporos Int. 2026. PMID: 42008163. doi:10.1007/s00198-026-08008-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。